GlassScriptPhysician profile
Nolan Johnson
NPI 1508382920
$2,734.81
in general payments reported to CMS, 2019-2025
34 companies · $533 in 2025
The $533 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,183 · 2024: $1,018 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.82 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $355.90 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $300.17 | 2023-2025 | |
| Novo Nordisk INC | $278.42 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $193.12 | 2023-2024 | Korlym |
| Exact Sciences Corporation | $134.33 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $130.32 | 2023-2025 | |
| Pfizer INC. | $128.50 | 2023-2025 | |
| Astellas Pharma US INC | $111.61 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $109.93 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $96.11 | 2023-2025 | Austedo Xr, Austedo |
| Amgen INC. | $90.88 | 2023-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $84.35 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $76.29 | 2023-2024 | Gemtesa |
| Esperion Therapeutics, INC. | $70.09 | 2023-2025 | Nexletol |
| Glaxosmithkline, LLC. | $68.30 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $47.99 | 2023 | Afrezza |
| Merck Sharp & Dohme LLC | $46.76 | 2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Paratek Pharmaceuticals, INC. | $42.30 | 2025 | Nuzyra, Xhance |
| Sanofi Pasteur INC. | $42.17 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $35.29 | 2023-2024 | Baqsimi |
| Xeris Pharmaceuticals, INC. | $32.40 | 2023-2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.56 | 2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $26.61 | 2024 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.42 | 2023 | Jardiance |
| Insulet Corporation | $24.16 | 2025 | Omnipod |
| Sequel Med Tech, LLC | $23.50 | 2025 | Twiist |
| Beta Bionics, INC. | $22.71 | 2024 | Ilet Bionic Pancreas |
| Medtronic, INC. | $19.27 | 2024 | Minimed 780g |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.00 | 2023 | Cycloset |
| Dexcom, INC. | $17.98 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $15.30 | 2023 | Vyepti |
| Alexion Pharmaceuticals, INC. | $15.22 | 2023 | Strensiq |
| Idorsia Pharmaceuticals US INC | $12.83 | 2023 | Quviviq |
| Cequr Corporation | $5.02 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.